Owen Mortimer Heath1, Heleen J van Beekhuizen2, Vivek Nama2, Desiree Kolomainen2, Marielle A E Nobbenhuis2, Thomas E J Ind3, Syed A Sohaib4, Fiona J Lofts5, Sue Heenan6, Martin Gore7, Susana Banerjee7, Stan B Kaye7, Desmond P J Barton3. 1. Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Lanesborough Wing, St. George's Hospital, Blackshaw Road, London, SW17 0QT, United Kingdom. Electronic address: owenheath@doctors.org.uk. 2. Department of Gynaecological Oncology, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, United Kingdom. 3. Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Lanesborough Wing, St. George's Hospital, Blackshaw Road, London, SW17 0QT, United Kingdom; Department of Gynaecological Oncology, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, United Kingdom. 4. Department of Radiology, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, United Kingdom. 5. Department of Oncology, St. Georges Hospital, Blackshaw Road, London, SW17 0QT, United Kingdom. 6. Department of Radiology, St. George's Hospital, Blackshaw Road, London, SW17 0QT, United Kingdom. 7. Department of Oncology, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, United Kingdom.
Abstract
OBJECTIVES: To determine the impact on survival of symptomatic and asymptomatic venous thromboembolism (VTE) at time of diagnosis of primary ovarian malignancy. MATERIALS AND METHODS: The clinical records of 397 consecutive cases of primary ovarian malignancy were studied. Clinical, pathological and survival data were obtained. RESULTS AND CONCLUSIONS: Of 397 cases, 19 (4.8%) were found to have VTE at diagnosis, of which 63.2% (n=12) were asymptomatic. VTE was significantly associated with reduced overall median survival (28 vs. 45 months, p=0.004). Decreased survival was associated with symptomatic VTE compared to patients with asymptomatic VTE (21 vs. 36 months, p=0.02) whose survival was similar to that of patients without VTE. Decreased survival remained significant in symptomatic patients after controlling for stage of disease at diagnosis, cytoreductive status and adjuvant chemotherapy use. Overall these data suggest for the first time that symptomatic but not asymptomatic VTE prior to primary treatment of ovarian cancer is an independent adverse prognostic factor.
OBJECTIVES: To determine the impact on survival of symptomatic and asymptomatic venous thromboembolism (VTE) at time of diagnosis of primary ovarian malignancy. MATERIALS AND METHODS: The clinical records of 397 consecutive cases of primary ovarian malignancy were studied. Clinical, pathological and survival data were obtained. RESULTS AND CONCLUSIONS: Of 397 cases, 19 (4.8%) were found to have VTE at diagnosis, of which 63.2% (n=12) were asymptomatic. VTE was significantly associated with reduced overall median survival (28 vs. 45 months, p=0.004). Decreased survival was associated with symptomatic VTE compared to patients with asymptomatic VTE (21 vs. 36 months, p=0.02) whose survival was similar to that of patients without VTE. Decreased survival remained significant in symptomatic patients after controlling for stage of disease at diagnosis, cytoreductive status and adjuvant chemotherapy use. Overall these data suggest for the first time that symptomatic but not asymptomatic VTE prior to primary treatment of ovarian cancer is an independent adverse prognostic factor.
Authors: Gabriella D Cozzi; Jacob M Samuel; Jason T Fromal; Spencer Keene; Marta A Crispens; Dineo Khabele; Alicia Beeghly-Fadiel Journal: BMC Cancer Date: 2016-08-08 Impact factor: 4.430